“Visit was calm and enjoyable. Staff professional and friendly. Impressed with high-tech equipment. Wait minimal. Never felt rushed with the doctor.”
Vabysmo Injections for Retinal Disease
Conditions Vabysmo Is Approved to Treat
Vabysmo is FDA-approved for three specific retinal conditions. Each of these conditions involves abnormal fluid or blood vessel changes in the retina that can threaten vision without treatment.
In wet AMD (age-related macular degeneration), abnormal blood vessels grow beneath the retina and leak fluid or blood. This damages the macula, the central portion of the retina responsible for sharp, detailed vision. Without treatment, wet AMD can cause rapid and significant central vision loss. Vabysmo reduces this leakage and can slow or improve vision loss, particularly when treatment begins early.
Diabetic macular edema (DME) develops when diabetes causes fluid to accumulate in the macula, blurring central vision and making everyday tasks like reading and driving more difficult. DME can occur at any stage of diabetic retinopathy and is one of the most common causes of vision loss in people with diabetes. Vabysmo reduces fluid buildup in the macula and can improve visual clarity over time. Managing blood sugar levels alongside injection treatment supports the best possible outcomes.
Retinal vein occlusion (RVO) occurs when a vein carrying blood away from the retina becomes blocked, causing swelling and fluid leakage in the macula. Vabysmo is approved to treat macular edema that develops as a result of RVO, reducing the swelling and protecting vision.
What Clinical Evidence Shows
Vabysmo was studied extensively in large clinical trials before approval, and real-world experience since its introduction has confirmed those results. This body of evidence gives our team confidence in how to use it effectively for each patient.
Two large clinical trials, TENAYA and LUCERNE, compared Vabysmo to aflibercept (Eylea) in patients with wet AMD. Results showed that Vabysmo was noninferior to Eylea in improving vision. Importantly, nearly 80 percent of wet AMD patients treated with Vabysmo were able to extend to at least 12-week injection intervals, and approximately 60 percent reached 16-week intervals after the initial loading phase.
The YOSEMITE and RHINE trials enrolled over 1,800 patients with DME. Patients treated with Vabysmo gained an average of 11 letters on a standardized eye chart over one year, comparable to results seen with Eylea. Studies also showed that a higher proportion of Vabysmo patients had complete clearance of retinal fluid at 12 weeks compared to those receiving aflibercept alone, suggesting a stronger drying effect in some patients.
Since Vabysmo became available, dozens of published real-world studies have confirmed that the results seen in clinical trials hold up in everyday clinical practice. These studies show that many patients can maintain their vision gains while receiving fewer injections per year compared to older anti-VEGF treatments.
What to Expect During Treatment
Knowing what the treatment schedule looks like from the start can help you plan and stay consistent with your care. The process is individualized, and your Retina Specialist will guide each step based on how your eye responds.
Treatment with Vabysmo begins with a loading phase of four monthly injections. These initial doses build up the medication in the eye and begin stabilizing the retina. During this period, you will visit your Retina Specialist once every four weeks.
After the loading phase, your Retina Specialist will use imaging tests and vision checks to determine whether injection intervals can be extended. Some patients can go as long as 16 weeks between doses. This personalized approach, often called treat-and-extend, adjusts your schedule based on how your retina is responding rather than following a fixed calendar.
Plan to spend approximately one to two hours at the office for each injection visit. Most of that time is spent on check-in, eye drops for dilation and numbing, and a brief monitoring period after the injection. The injection itself takes only seconds.
- Numbing drops are applied before the injection to minimize discomfort
- An antiseptic rinse is applied to reduce infection risk
- A brief sensation of pressure during the injection is common
- Mild redness or irritation after the visit typically resolves within a day or two
- Arrange for someone to drive you home, as your vision may be mildly blurred for several hours
Even as intervals extend, regular monitoring remains essential. At each visit, your Retina Specialist will check your vision and perform an OCT scan (optical coherence tomography, a painless imaging test that creates a detailed cross-section of the retina) to look for any remaining or returning fluid. These scans guide decisions about whether to maintain, extend, or shorten the time between injections.
Who May Benefit from Vabysmo
Vabysmo is not the right choice for every patient, but it is a strong option for several groups. Your Retina Specialist will evaluate your full history before recommending it.
Patients who have not yet received any anti-VEGF injections may be excellent candidates for Vabysmo. Clinical trials included a large proportion of treatment-naive patients and showed strong vision outcomes in this group. Starting with Vabysmo may allow patients to benefit from extended dosing intervals from the very beginning of their treatment.
Frequent injection appointments can be a real challenge, especially for patients who rely on others for transportation or who live a significant distance from a retinal practice. For patients who respond well, Vabysmo may meaningfully reduce the number of office visits per year, making it easier to stay consistent with care.
Patients already receiving anti-VEGF injections such as Avastin (bevacizumab), Lucentis (ranibizumab), or Eylea (aflibercept) may consider switching to Vabysmo. Common reasons include persistent retinal fluid despite regular injections or a goal of extending treatment intervals. Your Retina Specialist can assess whether switching is appropriate based on your specific condition and imaging findings.
How Vabysmo Compares to Other Anti-VEGF Medications
Several anti-VEGF medications are available for retinal conditions, and each has its own profile. Understanding the differences can help you have a more informed conversation with your Retina Specialist.
Eylea (aflibercept) and Lucentis (ranibizumab) are well-established anti-VEGF medications that target only VEGF-A. Both have strong long-term safety records built over more than a decade of clinical use. These medications typically require injections every four to eight weeks in most patients. Vabysmo's dual-target design allows many patients to extend intervals further while achieving comparable vision outcomes.
Avastin (bevacizumab) is used off-label for retinal conditions and was originally FDA-approved for cancer treatment. Large clinical studies have shown it to be effective for many patients, and it is considerably less expensive than other options. However, it generally requires more frequent dosing than newer agents. Vabysmo's ability to extend intervals may reduce the total number of visits per year for patients who are good candidates for it.
There is no single best anti-VEGF medication for every patient. Your Retina Specialist will consider your specific diagnosis, disease severity, treatment history, and personal preferences when recommending the right approach. Switching between medications when the initial treatment does not achieve the desired response is common and appropriate.
Safety Profile and Side Effects
Like all injectable retinal treatments, Vabysmo carries a small risk of side effects. Understanding these risks helps you recognize when to contact your care team promptly.
The most frequently reported side effects in clinical trials included cataract development and conjunctival hemorrhage (a small area of bleeding on the white of the eye). These side effects were generally mild and occurred at rates comparable to those seen with other anti-VEGF injections. Most injection-related side effects resolve on their own within a few days.
As with any intravitreal injection, there is a small risk of more serious complications. These include endophthalmitis (infection inside the eye), increased eye pressure, retinal detachment, and vitreous hemorrhage (bleeding inside the eye). Retinal vasculitis, which is inflammation of the blood vessels in the retina, has been reported rarely with Vabysmo. The overall rate of serious complications remains low, and strict sterile technique during every injection is used to minimize these risks.
After any injection, contact your Retina Specialist right away or go to an emergency room if you experience sudden vision loss, increasing eye pain, worsening redness, or a significant increase in floaters. These symptoms can be signs of a serious complication that requires prompt evaluation and treatment.
Frequently Asked Questions
These answers address common questions that go beyond the general information covered above, including practical guidance to help you navigate your treatment confidently.
Interval extension is evaluated after the four-injection loading phase is complete. At that point, your Retina Specialist reviews your OCT images and visual acuity results to determine whether your retina is stable enough to space out treatments. Some patients move to 8-week intervals initially, while others progress more quickly to 12 or 16 weeks. The pace is always guided by your individual response rather than a set schedule.
Vabysmo has shown strong results in both wet AMD and DME, though the conditions involve different disease processes. For DME specifically, managing systemic diabetes control alongside injections plays an important role in outcomes. Your Retina Specialist will factor in your underlying health status, not just the retinal findings, when setting expectations for your treatment.
Vision improvement is possible for many patients, especially when treatment begins early before significant retinal damage has occurred. However, results vary from person to person. Some patients regain meaningful visual function, while others experience stabilization that prevents further loss. Vision lost due to long-standing or advanced retinal damage may not be fully recoverable, which is why beginning treatment promptly after diagnosis is so important.
Contact your Retina Specialist's office as soon as possible to reschedule. Missing or delaying an injection, especially during the loading phase or during a period of active disease, can allow retinal fluid to return and vision to decline. Do not wait until your next regularly scheduled appointment if you have missed a visit; earlier rescheduling helps protect the progress you have made.
Intravitreal injections are generally considered safe for patients on anticoagulants (blood thinners), but it is important to share a complete list of your medications with your Retina Specialist before treatment begins. Certain systemic health conditions may affect your overall care plan. Your Retina Specialist and your other physicians can work together to ensure that your retinal treatment is coordinated safely with your broader health management.
For conditions like wet AMD, ongoing treatment is typically necessary to maintain vision, though intervals may lengthen over time as your eye stabilizes. For DME, treatment may eventually be paused if the condition fully resolves, but continued monitoring remains important to detect any recurrence early. Your Retina Specialist will reassess your long-term plan at every visit based on current imaging and vision data.
Start Your Retinal Care at Atlantic Retina Center
At Atlantic Retina Center, our fellowship-trained, board-certified team specializes exclusively in the retina, vitreous, and macula, bringing focused expertise to every patient we care for across the Eastern Shore of Maryland and central and southern Delaware. If you have been diagnosed with wet AMD, diabetic macular edema, or retinal vein occlusion, or if you have concerns about your retinal health, we are here to help you understand your options and create a personalized treatment plan. Our team uses advanced retinal imaging at every visit to track your progress with precision and make informed decisions about your care. We look forward to partnering with you to protect and preserve your vision.